Skip to main content
. 2022 Jan 20;8(3):385–392. doi: 10.1001/jamaoncol.2021.6818

Figure 2. Prediction of Overall Survival (OS) Using Radiomics Signature vs Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) in the Validation Set.

Figure 2.

The regulatory end point defined progression-free survival and overall response rate. In the pembrolizumab validation set (n = 287), trichotomized RECIST 1.1 response classified patients at 3 months as having a complete or partial response (93 of 287 [32.4%]), stable disease (90 of 287, [31.3%]), and progressive disease (104 of 287 [36.2%]). The signature was trichotomized from best to worse predicted prognosis using the same distribution as RECIST 1.1 (classified patients into 3 groups, including 32.4%, 31.3%, and 36.2% of patients as cutoffs to divide the signature results into top, middle, and bottom groups). The area under the time-dependent receiver operating characteristics curve for prediction of survival status at 6 months posttreatment landmark was 0.92 (95% CI, 0.89-0.95) for the continuous signature, 0.89 (95% CI, 0.86-0.92) for the trichotomized signature, and 0.80 (95% CI, 0.74-0.84) the trichotomized RECIST 1.1.